InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
3
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the full record of transactions filed by Stalfort John A III, 董事. Director active across 4 companies, notably Acumen Pharmaceuticals, Inc.. Aggregated, 8 disclosures have been published. Breakdown: 3 buys · 0 sell. Total volume traded: €809k. Activity tracked since 5 July 2022. The latest transaction was disclosed on 3 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Stalfort John A III
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
35,500 股0Common StockSEC:0001628280-26-041273:0
12,800 股0Common StockSEC:0001576885-25-000082:0
56,623 股0Common StockSEC:0001415889-25-015574:0
1,123,595 股Common StockSEC:0001415889-24-027710:0
标准退出：2025年2月20日 (T+90)
49,220 股0Common StockSEC:0001415889-24-015041:0
388,889 股@ US$0.90100.0% 占其流量Common StockSEC:0001209191-23-046152:0
标准退出：2023年11月14日 (T+90)
238,095 股@ US$2.10100.0% 占其流量Common StockSEC:0001209191-22-040591:0
标准退出：2022年10月3日 (T+90)
130,180 股Common StockSEC:0001209191-21-046030:0
8 条申报中的 8 条
About Stalfort John A III
Stalfort John A III is Administrateur at Acumen Pharmaceuticals, Inc., Taysha Gene Therapies, Inc. and Verrica Pharmaceuticals Inc. Across 8 filings in total, the 8 sampled filings run from 2021-07-08 to 2026-06-05, with EUR 809282 of buys and EUR 0 of sells, and the modal transaction nature is Attribution.
